This guidance introduces a new classification system with three broad categories of biomarkers: core AD biomarkers (Aβ and tau), non-specific biomarkers important in AD pathogenesis but also involved in other neuropathological diseases, and biomarkers of common, non-AD co-pathologies [41]. This evidence concerns the gene MAPT and Alzheimer disease.